InSynBio focuses on AI-assisted drug R&D. We leverage clinical and scientific literature data, combined with machine learning, to deliver AI-driven drug design and evaluation. Our approach integrates computational and experimental workflows (dry-wet combined), supporting clinical translation and drug innovation. Learn more →
InSynBio 专注 AI 辅助药物研发。我们基于临床与科学文献数据，结合机器学习，提供 AI 驱动的药物设计与评估。采用干湿结合方式，助力临床转化与药物创新。了解更多 →
All Services全部服务
InSynBio provides in silico assessment, design, and development services for biotherapeutics. Current and planned offerings:
InSynBio 提供生物治疗药物的 in silico 评估、设计与开发服务。当前及规划中的服务：
| Service服务 | Status状态 | Description描述 |
|---|---|---|
| Antibody In Silico Assessment & Development抗体 In Silico 评估与开发 | Available已上线 | Sequence analysis, developability, immunogenicity, structure, humanization, affinity maturation序列分析、可开发性、免疫原性、结构、人源化、亲和力成熟 |
| CAR-T DesignCAR-T 设计 | Coming soon敬请期待 | CAR construct design and optimizationCAR 构建设计与优化 |
| Bispecific Antibody Design双特异性抗体设计 | Coming soon敬请期待 | BsAb format selection and sequence designBsAb 格式选择与序列设计 |
| More services更多服务 | Planned规划中 | Additional offerings to be announced更多服务即将推出 |
Antibody Developability Assessment抗体可开发性评估
Expert-reviewed computational antibody analysis, evaluation, and gene-engineering humanization for drug discovery and development.
专家审核的计算抗体分析、评估与基因工程人源化，服务于药物发现与开发。
Disclaimer: InSynBio in silico analyses are for reference only and do not replace final wet-lab validation. Experimental confirmation is required.
免责声明：InSynBio 的 in silico 分析仅供参考，不能替代最终湿实验验证。需进行实验确认。
Platform平台
The Antibody Developability Assessment platform provides computational analysis, evaluation, gene-engineering humanization, and structure-driven affinity maturation for antibody drug discovery and development. We primarily work from sequences—submit VH/VL or VHH sequences online; we can model structures in-house when needed. Our experts deliver structured reports covering numbering, germline retrieval, developability, immunogenicity, structure assessment, interface analysis, humanization design, and affinity maturation.
抗体可开发性评估平台提供计算分析、评估、基因工程人源化及结构驱动亲和力成熟服务，服务于抗体药物发现与开发。我们以序列为主——在线提交 VH/VL 或 VHH 序列即可；需要时我们可自行建模。专家将交付涵盖编号、胚系检索、可开发性、免疫原性、结构评估、界面分析、人源化设计与亲和力成熟的结构化报告。
All services are expert-reviewed and delivered offline—typically within 3–5 business days upon project confirmation. Our pipeline is based on 1,142 clinical antibody sequences and uses transparent metrics. Humanization employs structure-driven back-mutations and prioritizes germlines from clinical antibodies. Structure assessment is included for all humanization deliverables.
所有服务均经专家审核，线下交付——通常在项目确认后 3–5 个工作日内完成。我们的流程基于 1,142 条临床抗体序列，采用透明指标。人源化采用结构驱动回突变，优先使用临床抗体胚系。所有人源化交付物均包含结构评估。
Sequence序列
Sequence Analysis
序列分析
- Numbering and CDR annotation — IMGT/Kabat schemes, FR/CDR delineation
- Germline retrieval — Nearest germline and identity (%) against 1,142 clinical antibody sequences
- VH/VL pairing — Co-occurrence frequency in clinical antibodies
- 编号与 CDR 注释 — IMGT/Kabat 方案，FR/CDR 界定
- 胚系检索 — 最近胚系及与 1,142 条临床抗体序列的 identity (%)
- VH/VL 配对 — 临床抗体中的共现频率
Input: VH/VL sequences
输入：VH/VL 序列
Developability可开发性
Developability and CMC
可开发性与 CMC
- Physicochemical — pI, GRAVY, instability index, net charge
- SAP — 9-mer hydrophobic and 7-mer charge aggregation propensity
- CDR chemical risk — Deamidation (NG/NS), oxidation (M/W), glycosylation (NxS/T), free Cys
- TAP — Total CDR length, PSH, PPC, PNC, SFvCSP (InSynBio in-house implementation with reference thresholds). Requires PDB and CDR sequences.
- CMC design — pI adjustment, FR-only mutation suggestions
- 理化 — pI、GRAVY、不稳定指数、净电荷
- SAP — 9-mer 疏水与 7-mer 电荷聚集倾向
- CDR 化学风险 — 脱酰胺(NG/NS)、氧化(M/W)、糖基化(NxS/T)、游离 Cys
- TAP — Total CDR length、PSH、PPC、PNC、SFvCSP（InSynBio 自研，含参考阈值）。需 PDB 与 CDR 序列。
- CMC 设计 — pI 调整、FR-only 突变建议
Input: VH/VL sequences. For TAP: PDB and CDR sequences are required.
输入：VH/VL 序列。TAP 需 PDB 与 CDR 序列。
Immunogenicity免疫原性
Immunogenicity Assessment
免疫原性评估
- MHC-II 27 alleles — IEDB prediction, FR surface risk assessment
- Risk clustering — Agglomerative clustering of high-risk positions
- Surface immunogenicity — Parker hydrophilicity; SASA-based analysis (optional when PDB is provided)
- Germline tolerance — IGHV/IGKV/IGLV frequency-weighted filter
- MHC-II 27 等位基因 — IEDB 预测、FR 表面风险评估
- 风险聚类 — 高风险位点凝聚聚类
- 表面免疫原性 — Parker 亲水性；SASA 分析（提供 PDB 时可选）
- 胚系耐受 — IGHV/IGKV/IGLV 频率加权过滤
Input: VH/VL sequences (PDB optional)
输入：VH/VL 序列（PDB 可选）
Structure结构
Structure and Interface
结构与界面
- Whole antibody (Fab) assessment — 13-parameter evaluation: VH-VL angle, interface contacts, Vernier SASA, CDR conformation, pLDDT
- VHH assessment — Single-domain structure metrics, CDR conformation, pLDDT
- Antigen-antibody complex assessment — Antibody-antigen interface: BSA, paratope/epitope residues, H-bonds, salt bridges, hydrophobic contacts
- Multi-antibody comparison — Epitope overlap, competition analysis, BSA/SC comparison (on request)
- 全抗体 (Fab) 评估 — 13 参数：VH-VL 夹角、界面接触、Vernier SASA、CDR 构型、pLDDT
- VHH 评估 — 单域结构指标、CDR 构型、pLDDT
- 抗原-抗体复合物评估 — BSA、paratope/epitope 残基、H 键、盐桥、疏水接触
- 多抗体比较 — 表位重叠、竞争分析、BSA/SC 对比（按需）
Input: PDB (Fab, VHH, or antigen-antibody complex). Antigen chain ID required for interface analysis.
输入：PDB（Fab、VHH 或抗原-抗体复合物）。界面分析需抗原链 ID。
Affinity Maturation亲和力成熟
Structure-Driven Affinity Maturation
结构驱动亲和力成熟
Based on existing complex structures. No de novo structure generation required. Structure assessment included for all deliverables.
基于现有复合物结构。无需从头结构生成。所有交付物均含结构评估。
- Antigen-antibody affinity maturation — CDR redesign on Ab-Ag complex backbone for improved binding
- Ligand-receptor affinity maturation — Paratope optimization on ligand-receptor complex for enhanced affinity
- VHH affinity maturation — CDR optimization on VHH-antigen complex for single-domain antibodies
- 抗原-抗体亲和力成熟 — 基于 Ab-Ag 复合物骨架的 CDR 重设计，提升结合
- 配体-受体亲和力成熟 — 配体-受体复合物上的 paratope 优化
- VHH 亲和力成熟 — VHH-抗原复合物上的 CDR 优化
Input: PDB of existing complex (Ab-Ag, ligand-receptor, or VHH-antigen). Design region (e.g., CDR-H3) specified per project.
输入：现有复合物 PDB。设计区域（如 CDR-H3）按项目指定。
Humanization人源化
Gene-Engineering Humanization Services
基因工程人源化服务
All humanization deliverables include structure assessment. Our VH/VL pipeline employs structure-driven back-mutations and prioritizes germlines derived from 1,142 clinical antibody sequences.
所有人源化交付物均含结构评估。VH/VL 流程采用结构驱动回突变，优先使用 1,142 条临床抗体序列胚系。
| Service服务 | Input输入 | Technology技术 |
|---|---|---|
| VH/VL HumanizationVH/VL 人源化 | Mouse VH and VL鼠源 VH 与 VL | AbEngineCore V4.4 pipeline. Structure-driven back-mutations with prioritization of germlines from 1,142 clinical antibody sequences. CDR grafting with surface reshaping fallback. Structure assessment included.AbEngineCore V4.4 流程。结构驱动回突变，优先 842 条临床抗体胚系。CDR 移植 + 表面重塑备选。含结构评估。 |
| VHH HumanizationVHH 人源化 | Camelid or llama VHH驼源或羊驼 VHH | Integrated approach combining surface reshaping and framework grafting. Preserves CDRs and structural hallmarks. Structure assessment included.表面重塑与框架移植结合。保留 CDR 与结构特征。含结构评估。 |
| VH to VHH ConversionVH 转 VHH | Conventional VH (from mAb)常规 VH（来自 mAb） | CDR grafting onto human VHH scaffold with structure-guided optimization. Expert design service. Structure assessment included.CDR 移植至人源 VHH 骨架，结构引导优化。专家设计服务。含结构评估。 |
Full Report完整报告
Full Evaluation Report
完整评估报告
Comprehensive integrated report covering sequence, germline, developability, immunogenicity, structure, and interface analysis. Delivered in Markdown or PDF format, with optional JSON. Typically completed within 3–5 business days upon project confirmation.
涵盖序列、胚系、可开发性、免疫原性、结构与界面分析的综合报告。Markdown 或 PDF 交付，可选 JSON。通常项目确认后 3–5 个工作日完成。
Input: VH/VL sequences (PDB optional)
输入：VH/VL 序列（PDB 可选）
Submit Inquiry提交咨询
Complete the form below with your sequences and requirements. We will review your submission and provide a quote within 1–2 business days.
请填写下方表单，提交序列与需求。我们将在 1–2 个工作日内审核并回复报价。
Contact联系方式
For inquiries, please submit the form above or email us directly:
咨询请使用上方表单或直接发送邮件：
We typically respond within 1–2 business days.
我们通常在 1–2 个工作日内回复。